CAS: 399-88-2; 3-Fluoro-4-Methylpyridine

该化合物是三方位以氟原子取代的环状和四方位的甲基组的热循环有机化合物,其分子式为C6H6FNF,表明存在6个碳原子,6个氢原子,1个氟原子和1个氮原子.该化合物一般表现为无色至浅黄色液体,有独特的气味.它溶于有机溶剂,并表现出中极性,因为芳香环中存在氮原子. 3-Fluoro-4-甲基在各种化学合成中使用,可以作为制药和农用化学品生产的中间体.它的再活性受氟亚成分的电阻性质的影响,这种物质会影响核糖和电荷反应.在处理这一化合物时,应当采取安全防范措施,因为如果吸入或吸入,可能会对健康造成危害.

结构式图片

相似化合物

1196156-81-6 40273-47-0 113770-88-0

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号372-47-4 3-氟吡啶 | CAS号74-88-4 碘甲烷 | CAS号3430-27-1 3-氨基-4-甲基吡啶 | CAS号23056-33-9 2-氯-4-甲基-5-硝基吡啶 | CAS号21901-41-7 2-羟基-4-甲基-5-硝基吡啶 | CAS号21901-40-6 2-氨基-4-甲基-5-硝基吡啶 | CAS号6635-86-5 2-氨基-4-甲基-3-硝基吡啶 | CAS号21901-18-8 2-羟基-4-甲基-3-硝基吡啶 | CAS号23056-39-5 2-氯-4-甲基-3-硝基吡啶 | CAS号695-34-1 2-氨基-4-甲基吡啶 | CAS号393-53-3 3-氟吡啶-4-羧酸 | CAS号40273-47-0 3-氟吡啶-4-甲醛 | CAS号343-72-6 3-氟-异烟酸乙酯 | CAS号312904-99-7 2-Pyridinecarbo...

合成工艺路线路线简述

    2-氯-5-硝基-4-甲基吡啶置于palladium On Activated Charcoal,亚硝酸乙酯,Sodium Acetate,溶剂黄146,Petroleum Ether体系中,化学反应生成3-氟-4-甲基吡啶
    参考文献:The Preparation Of 3-Fluoroisonicotinic Acid And Related Compounds
    标题:The Preparation Of 3-Fluoroisonicotinic Acid And Related Compounds
    摘要:
    Doi:10.1021/jo01364A020

    海关参考信息

    专利信息


    专利号:US-8338451-B2
    优先权日:2008-03-21
    标 题 :Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof
    发明人:DE PERETTI DANIELLE; EVANNO YANNICK; LARDENOIS PATRICK; MACHNIK DAVID; RAKOTOARISOA NATHALIE; ALMARIO GARCIA ANTONIO
    权利人:DE PERETTI DANIELLE; EVANNO YANNICK; LARDENOIS PATRICK; MACHNIK DAVID; RAKOTOARISOA NATHALIE; ALMARIO GARCIA ANTONIO; SANOFI SA
    摘要:Compounds of formula (I): n nwherein R, R 1 , R 2 , R 3 , R 4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

    专利号:US-8362019-B2
    优先权日:2008-02-01
    标 题:Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyrazine compounds
    发明人:WINFIELD LEYTE L
    权利人:SPELMAN COLLEGE; WINFIELD LEYTE L
    摘要:This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated. In particular, the disclosure provides for substituted imidazo[4,5-b]pyrazine compounds having the general formula n ntheir salts, pharmaceutical compositions, and methods of treatment using the subject compounds and compositions.

    专利号:US-2012095038-A1
    优先权日:2008-02-01
    标 题:Synthesis and anti-proliferative effect of benzimidazole derivatives

    专利号:WO-2014158302-A1
    优先权日:2013-03-25
    标 题:Novel sphingosine 1-phosphate receptor antagonists
    发明人:SWENSON ROLF ERIC
    权利人:SWENSON ROLF ERIC
    摘要:The present invention relates to sphingosine-1 -phosphate (S1 P) receptors and compounds of the general formula (1), that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1 -phosphate receptor 2 (S1 P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1 P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1 P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

    专利号:US-8536164-B2
    优先权日:2010-12-20
    标 题:Fused pyridine compounds as casein kinase inhibitors
    发明人:BUTLER TODD W; CHANDRASEKARAN RAMALAKSHMI Y; MENTE SCOT R; SUBRAMANYAM CHAKRAPANI; WAGER TRAVIS T
    权利人:BUTLER TODD W; CHANDRASEKARAN RAMALAKSHMI Y; MENTE SCOT R; SUBRAMANYAM CHAKRAPANI; WAGER TRAVIS T; PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: n nand pharmaceutically acceptable salts thereof, wherein X, Y, A, R 4 , n, and R 7 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-2012095009-A1
    优先权日:2008-02-01
    标题 :Synthesis and anti-proliferative effect of benzimidazole derivatives
    阜新金特莱氟化学有限责任公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.jtlchem.com
    企业联系电话:0418-8229899👤
    📞阜新金特莱氟化学有限责任公司 ⚠️参考联系方式
    联系人:那经理
    电话:0418-8229899

    传真:0418-8229699
    邮箱:natj@jtlchem.com
    通信地址: 辽宁省阜新氟产业开发区化工七路5号(阜蒙县伊吗图镇)
    邮编: 123129
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:辽宁省阜新氟产业开发区化工七路5号(阜蒙县伊吗图镇)
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    阜新煜科化工科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yukechem.com
    企业联系电话:0418-6696667👤
    📞阜新煜科化工科技有限公司 ⚠️参考联系方式
    联系人:刘先生
    电话:0418-6696667
    手机:15724496333;15042569933

    邮箱:sales@yukechem.com
    通信地址: 新邱区永兴路9号
    邮编: 123000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:新邱区永兴路9号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1038/s41557-021-00757-4
    摘要:Zhu J, Zhang R, Dong G. Orthogonal cross-coupling through intermolecular metathesis of unstrained C(aryl)-C(aryl) single bonds. Nat Chem. 2021 Sep;13(9):836–42. doi: 10.1038/s41557-021-00757-4.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知